The North American pharma industry experienced a 26% drop in new job postings in Q3 2023 compared with the previous quarter, with the highest share accounted for by CSL with 3,389 job postings, according to GlobalData’s analysis of pharma company job postings. GlobalData’s Pharma: Hiring Trends & Signals Q3 2023 report reveals comprehensive insights into hiring patterns, job roles, required skills, geographical trends, and key themes within the pharmaceuticals industry, facilitating anticipation of future workforce needs. Buy the report here.
Notably, Management Occupations jobs accounted for a 20% share of the North American pharma industry’s total new job postings in Q3 2023, drop 41% over the prior quarter.
Management Occupations drive pharma industry hiring activity
Management Occupations, with a share of 20% new job postings, was the occupation with the greatest hiring activity in the North American pharma industry in Q3 2023 , ahead of Life, Physical, and Social Science Occupations with a 10% share of new job postings.
The other prominent roles included Healthcare Practitioners and Technical Occupations with an 8% share in Q3 2023, Sales and Related Occupations with a 6% share and Healthcare Support Occupations with a 6% share of new job postings.
Top five companies accounted for 34% of hiring activity
CSL posted 3,389 jobs in Q3 2023 and registered a growth of 37% over the previous quarter, followed by Grifols with 2,827 jobs and a 75% growth. Merck, with 1,804 jobs, and Charles River Laboratories International, with 1,356 jobs, recorded a 26% drop and a 9% drop, respectively, while Pfizer recorded a 46% decline with a 1,153 new job postings during Q3 2023.
Regional analysis of hiring in the North American pharma industry, Q3 2023
The US held the leading share of the North American pharma hiring activity with a 92.39% share, a 25% decrease over Q2 2023. Canada was next with 4.21%, four-percentage-point down over the previous quarter.
For further understanding of GlobalData's Pharma: Hiring Trends & Signals Q3 2023, buy the report here.